Meeder Advisory Services Inc. Sells 1,566 Shares of Pfizer Inc. (NYSE:PFE)

Meeder Advisory Services Inc. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.5% in the fourth quarter, HoldingsChannel reports. The fund owned 60,218 shares of the biopharmaceutical company’s stock after selling 1,566 shares during the quarter. Meeder Advisory Services Inc.’s holdings in Pfizer were worth $1,598,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. First Wilshire Securities Management Inc. bought a new position in shares of Pfizer in the fourth quarter worth about $244,000. Knott David M Jr raised its stake in Pfizer by 13.4% during the 4th quarter. Knott David M Jr now owns 254,537 shares of the biopharmaceutical company’s stock worth $6,753,000 after acquiring an additional 30,000 shares during the period. Trexquant Investment LP lifted its holdings in Pfizer by 6.0% during the fourth quarter. Trexquant Investment LP now owns 765,736 shares of the biopharmaceutical company’s stock valued at $20,315,000 after purchasing an additional 43,193 shares in the last quarter. Centric Wealth Management boosted its position in shares of Pfizer by 175.1% in the fourth quarter. Centric Wealth Management now owns 85,997 shares of the biopharmaceutical company’s stock worth $2,282,000 after purchasing an additional 54,736 shares during the period. Finally, Boston Family Office LLC increased its stake in shares of Pfizer by 2.4% in the fourth quarter. Boston Family Office LLC now owns 67,845 shares of the biopharmaceutical company’s stock worth $1,800,000 after purchasing an additional 1,563 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.06% of the company’s stock.

Pfizer Price Performance

PFE stock opened at $24.73 on Thursday. The company has a fifty day simple moving average of $25.98 and a two-hundred day simple moving average of $26.83. Pfizer Inc. has a 52 week low of $24.31 and a 52 week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $140.26 billion, a P/E ratio of 17.54, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter last year, the business posted $0.10 earnings per share. The firm’s revenue was up 24.7% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on PFE shares. Citigroup dropped their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Bank of America reiterated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Finally, Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.